gucy2c cart cells
Cell therapyexperimental
Clinical trial activity
2 trials · 3 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
0
Phase 3
0
Phase 4
0
Earliest trial started Oct 10, 2020 (NCT04652219)
Timeline
2020s
- Jan 1, 2020
Earliest Phase 1 Sponsor(trial)
Indications
Studied for
Mechanism of action
- Heat-stable enterotoxin receptorImmunity, passive
GUCY2C immunity, passive
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT04780529 | N/A | Mar 31, 2021 | Anhui Medical University, Innovative Cellular Therapeutics Co., Ltd. |
| NCT04652219 | Early Phase 1 (Phase 1) | Oct 10, 2020 | Innovative Cellular Therapeutics Co., Ltd., Zhejiang University |
Showing 2 of 2 trials
Page 1 / 1
Organizations
Research & Development (3)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Innovative Cellular Therapeutics Co., Ltd. | For profit | 2 | 1 | 2 | 2020 |
| Anhui Medical University | Academic/Hospital | 1 | 0 | 1 | 2021 |
| Zhejiang University | Academic/Hospital | 1 | 1 | 1 | 2020 |
3 organizations
Page 1 / 1